ScoreWhy is Jiangxi Fushine Pharmaceutical Co., Ltd. ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 4.17%
- Poor long term growth as Net Sales has grown by an annual rate of -2.90% and Operating profit at -34.60% over the last 5 years
- The company is Net-Debt Free
2
With a growth in Net Profit of 692.07%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 2 consecutive quarters
- ROCE(HY) Highest at 0.18%
- RAW MATERIAL COST(Y) Fallen by -299.89% (YoY)
- NET SALES(Q) At CNY 357.76 MM has Grown at 20.76%
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 88.20%, its profits have risen by 99.1%
4
Market Beating performance in long term as well as near term
- Along with generating 88.20% returns in the last 1 year, the stock has outperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Jiangxi Fushine Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Jiangxi Fushine Pharmaceutical Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Jiangxi Fushine Pharmaceutical Co., Ltd.
88.2%
1.42
60.07%
China Shanghai Composite
21.31%
1.56
13.67%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-2.90%
EBIT Growth (5y)
-34.60%
EBIT to Interest (avg)
1.19
Debt to EBITDA (avg)
25.53
Net Debt to Equity (avg)
0.58
Sales to Capital Employed (avg)
0.30
Tax Ratio
2.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.17%
ROE (avg)
2.55%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.12
EV to EBIT
190.00
EV to EBITDA
45.32
EV to Capital Employed
2.36
EV to Sales
6.31
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1.24%
ROE (Latest)
-0.11%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend32What is working for the Company
ROCE(HY)
Highest at 0.18%
RAW MATERIAL COST(Y)
Fallen by -299.89% (YoY
NET SALES(Q)
At CNY 357.76 MM has Grown at 20.76%
OPERATING PROFIT(Q)
Highest at CNY 74.75 MM
OPERATING PROFIT MARGIN(Q)
Highest at 20.89 %
PRE-TAX PROFIT(Q)
Highest at CNY 59.6 MM
NET PROFIT(Q)
Highest at CNY 61.6 MM
EPS(Q)
Highest at CNY 0.11
-11What is not working for the Company
INTEREST(HY)
At CNY 28.6 MM has Grown at 40.14%
OPERATING CASH FLOW(Y)
Lowest at CNY 43.75 MM
CASH AND EQV(HY)
Lowest at CNY 956.26 MM
Here's what is working for Jiangxi Fushine Pharmaceutical Co., Ltd.
Pre-Tax Profit
At CNY 59.6 MM has Grown at 574.77%
over average net sales of the previous four periods of CNY -12.55 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 61.6 MM has Grown at 558.42%
over average net sales of the previous four periods of CNY -13.44 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Net Sales
At CNY 357.76 MM has Grown at 20.76%
over average net sales of the previous four periods of CNY 296.25 MMMOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Operating Profit
Highest at CNY 74.75 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Operating Profit Margin
Highest at 20.89 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at CNY 59.6 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Net Profit
Highest at CNY 61.6 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
EPS
Highest at CNY 0.11
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Raw Material Cost
Fallen by -299.89% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Jiangxi Fushine Pharmaceutical Co., Ltd.
Interest
At CNY 28.6 MM has Grown at 40.14%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Operating Cash Flow
Lowest at CNY 43.75 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (CNY MM)
Cash and Eqv
Lowest at CNY 956.26 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
